NEW YORK (Bloomberg) -- Pfizer Inc. now expects its Covid-19 vaccine to bring in US$33.5 billion in revenue this year, putting it on course to become one of the best-selling medicines of all time.
The New York drugmaker had previously projected vaccine sales for the year of US$26 billion. The upward revision is a sign demand for the shots, which Pfizer sells with German partner BioNTech SE, is surging as countries battle new outbreaks fueled by the delta virus variant.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!